We are really pleased to announce that we will be present in BioAsia-Taiwan and present our breakthrough technology BIOMIMESYS alongside our partners Molecular Devices (USA) and LumiSTAR Biotechnology (TW). We are 3 companies in 3 different continents unifying their strenghs to develop the best strategy to find new and more Read more…
Welcome to HCS Pharma series of webinars and please register for free to the ones you want to attend. You will receive the specific Zoom link within a week prior the event.You will learn more about BIOMIMESYS®, an amazing and disruptive technology that reproduces all aspects of the microenvironment (matrix Read more…
Poster presented during the SLAS event in San Diego on the 27th and 28th of February 2023. Title: BIOMIMESYS® Hydroscaffold, a ready-to-use organ-specific Extracellular Matrix for Relevant Phenotypic Screening Dr. Nathalie Maubon*, Dr. Véronique De Conto, Dr. Méryl Roudaut, Dr Alejandra Mogrovejo – Valdivia, Julien Leriche, Vaihere Cheung and Dr Read more…
High Throughput Screening (HTS) has been developed in the 80s, in the context of the automation and miniaturization of techniques for biological assays. Thanks to multiwell plates (96, 384, 1536, or 3456 wells) handled on a platform with robotic arms and automated pipetting systems, it allows to test hundreds of Read more…
Growing interest in phenotypic screening, together with evidence that the drug response of cells grown in three-dimensional (3D) structures more closely resembles in vivo activity, has made high throughput, 3D fluorescence imaging an attractive screening option for drug discovery. However, creating 3D spheroids compatible with high content screening can be Read more…
Our CEO, Nathalie is the Chairwoman of the session “ Next Generation High-Content Bioimaging – Phenotypic Discovery” (Track 3 – session 2) at next SLAS Barcelona event. This event will bring together more than 1,000 scientists and technologists from around the world. The theme for the 2019 Europe Conference is Read more…
Thank to our partner Integra Biosciences, we are happy to present you an application note about a straightforward workflow for 3D cell seeding and spheroid formation using HCS Pharma’s BIOMIMESYS® plates in combination with INTEGRA’s VIAFLO 96/384 pipetting system and without forgetting to mention with the use of our imageXpress micro confocal Read more…
Next week (the 23th and the 24th of May), we will be in Strasbourg to participate to ELRIGfr event, where we will present two posters. The first poster is about BIOMIMESYS® hydroscaffold for 3D cell culture and the compatibility with automation; the plates can be seeded, treated easily using the VIAFLO 96/384. Read more…
Curious about our toxicology and phenotypic screening services ?
We will talk about advantages of 3D culture in phenotypic screening
HCS/HCA is a great way to predict drugs toxicity
In this article, they employed microglia-based phenotypic screenings to search for small molecules that modulate the release of detrimental proinflammatory cytokines
After having been eclipsed by Target-Based Screening, Phenotypic Screening is finally shining again
Using iPS, researchers are moving very quickly in understanding cell differentiation and already manage to recreate a mini-organ in vitro after 20-30 days of differentiation
To incresase the relevance of the early stage of drug research process, using patient derived-cells is really the good way. This can be now feasible by using iPSCs.
The author has reported te use of phenotypic screening to find coumpound which has neuronal differenciation effect of stem cells.
By phenotypic screening, these authors have identified small molecules, that protected podocytes against injury in vitro. This findings identify pyrintegrin as a potential therapeutic candidate and show the use of podocyte-based screening assays for identifying novel therapeutics for proteinuric kidney diseases.
More and more articles show the advantages of #3d culture compared to 2D in #oncology field. This article describe how to do high throughput using 3D culture by rapid size profiling analysis over time on tumor spheroids. “Tumor size is the most frequently used in vivo endpoint when assessing antitumor efficacy in Read more…
In this presentation, Dr. Kamyar Hadian (head of the #assay development and Screening Platform’ at the HelmholtzZentrum München in Munich/Germany) talk about #hcs use in #stem cell– and microtissue-based assays. #phenotypic screening has highly emerged in the past years. Especially High-Content Screening (HCS) has gained strong acceptance in the field Read more…
I was really impressed by the size and quality of the Drug Discovery 2014 organised by ELRIG in Manchester. More than 1,500 scientists participated in this meeting and nearly 100 exhibitors were present. Phentoypic screening and high content screening were prominent in this conference and we could hear researchers from Roche, Astrazeneca, Read more…
The Scottish Government believes in the new strategy of phenotypic screening rather than target screening since they invest £8 million for university of Dundee and as they said: “Phenotypic screening is thought to be a powerful method for drug discovery because it offers the opportunity to go beyond the focus on single drug Read more…
“While classical screens with a single readout only allow you to quantify the measured effect, high-content screens promise more: Additional phenotypic changes can be observed and also quantified, allowing in principle a distinction of the chemical responses into three classes: similar to untreated cells; similar to control-treated cells; or dissimilar Read more…